These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 34919695)

  • 21. Combined treatment with the histone deacetylase inhibitor LBH589 and a splice-switch antisense oligonucleotide enhances SMN2 splicing and SMN expression in Spinal Muscular Atrophy cells.
    Pagliarini V; Guerra M; Di Rosa V; Compagnucci C; Sette C
    J Neurochem; 2020 Apr; 153(2):264-275. PubMed ID: 31811660
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cell-mediated cytotoxicity within CSF and brain parenchyma in spinal muscular atrophy unaltered by nusinersen treatment.
    Lu IN; Cheung PF; Heming M; Thomas C; Giglio G; Leo M; Erdemir M; Wirth T; König S; Dambietz CA; Schroeter CB; Nelke C; Siveke JT; Ruck T; Klotz L; Haider C; Höftberger R; Kleinschnitz C; Wiendl H; Hagenacker T; Meyer Zu Horste G
    Nat Commun; 2024 May; 15(1):4120. PubMed ID: 38750052
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nusinersen Modulates Proteomics Profiles of Cerebrospinal Fluid in Spinal Muscular Atrophy Type 1 Patients.
    Bianchi L; Sframeli M; Vantaggiato L; Vita GL; Ciranni A; Polito F; Oteri R; Gitto E; Di Giuseppe F; Angelucci S; Versaci A; Messina S; Vita G; Bini L; Aguennouz M
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33919289
    [TBL] [Abstract][Full Text] [Related]  

  • 24. AAV9-mediated delivery of miR-23a reduces disease severity in Smn2B/-SMA model mice.
    Kaifer KA; Villalón E; O'Brien BS; Sison SL; Smith CE; Simon ME; Marquez J; O'Day S; Hopkins AE; Neff R; Rindt H; Ebert AD; Lorson CL
    Hum Mol Genet; 2019 Oct; 28(19):3199-3210. PubMed ID: 31211843
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of the neurofilament light chain as a biomarker in children with spinal muscular atrophy treated with nusinersen.
    Seo G; Kim S; Byun JC; Kwon S; Lee YJ
    Brain Dev; 2023 Nov; 45(10):554-563. PubMed ID: 37541812
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Unilateral interlaminar fenestration on the convex side provides a reliable access for intrathecal administration of nusinersen in spinal muscular atrophy: a retrospective study.
    Wang Z; Feng E; Jiao Y; Zhao J; Chen X; Zhang H; Liang J; Li Z; Cui X; Chen W; Shen J
    Orphanet J Rare Dis; 2023 Nov; 18(1):369. PubMed ID: 38031122
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nusinersen treatment of spinal muscular atrophy - a systematic review.
    Albrechtsen SS; Born AP; Boesen MS
    Dan Med J; 2020 Aug; 67(9):. PubMed ID: 32800069
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nusinersen treatment and cerebrospinal fluid neurofilaments: An explorative study on Spinal Muscular Atrophy type 3 patients.
    Faravelli I; Meneri M; Saccomanno D; Velardo D; Abati E; Gagliardi D; Parente V; Petrozzi L; Ronchi D; Stocchetti N; Calderini E; D'Angelo G; Chidini G; Prandi E; Ricci G; Siciliano G; Bresolin N; Comi GP; Corti S; Magri F; Govoni A
    J Cell Mol Med; 2020 Mar; 24(5):3034-3039. PubMed ID: 32032473
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MiR34 contributes to spinal muscular atrophy and AAV9-mediated delivery of MiR34a ameliorates the motor deficits in SMA mice.
    Chen TH; Chang SH; Wu YF; Yen YP; Hsu FY; Chen YC; Ming Y; Hsu HC; Su YC; Wong ST; Hung JH; Chiou SH; Jong YJ; Chen JA
    Mol Ther Nucleic Acids; 2023 Jun; 32():144-160. PubMed ID: 37064776
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Longitudinal prospective cohort study to assess peripheral motor function with extensive electrophysiological techniques in patients with Spinal Muscular Atrophy (SMA): the SMA Motor Map protocol.
    Ros LAA; Goedee HS; Franssen H; Asselman FL; Bartels B; Cuppen I; van Eijk RPA; Sleutjes BTHM; van der Pol WL; Wadman RI
    BMC Neurol; 2023 Apr; 23(1):164. PubMed ID: 37095427
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Real-world safety and effectiveness of nusinersen, a treatment for spinal muscular atrophy, in 401 Japanese patients: results from an interim analysis of post-marketing surveillance.
    Tachibana Y; Takasaki S; Hoshino M; Makioka H; Jin M
    Int J Neurosci; 2024 Jun; 134(2):153-162. PubMed ID: 35787224
    [No Abstract]   [Full Text] [Related]  

  • 32. Treatment expectations and patient-reported outcomes of nusinersen therapy in adult spinal muscular atrophy.
    Osmanovic A; Ranxha G; Kumpe M; Müschen L; Binz C; Wiehler F; Paracka L; Körner S; Kollewe K; Petri S; Schreiber-Katz O
    J Neurol; 2020 Aug; 267(8):2398-2407. PubMed ID: 32361837
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of putative CSF biomarkers in paediatric spinal muscular atrophy (SMA) patients before and during treatment with nusinersen.
    Johannsen J; Weiss D; Daubmann A; Schmitz L; Denecke J
    J Cell Mol Med; 2021 Sep; 25(17):8419-8431. PubMed ID: 34312963
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Decreased Motor Neuron Support by SMA Astrocytes due to Diminished MCP1 Secretion.
    Martin JE; Nguyen TT; Grunseich C; Nofziger JH; Lee PR; Fields D; Fischbeck KH; Foran E
    J Neurosci; 2017 May; 37(21):5309-5318. PubMed ID: 28450545
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biomarkers of therapeutic efficacy in adolescents and adults with 5q spinal muscular atrophy: a systematic review.
    Gavriilaki M; Papaliagkas V; Stamperna A; Moschou M; Notas K; Papagiannopoulos S; Arnaoutoglou M; Kimiskidis VK
    Acta Neurol Belg; 2023 Oct; 123(5):1735-1745. PubMed ID: 35861914
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Modeling the differential phenotypes of spinal muscular atrophy with high-yield generation of motor neurons from human induced pluripotent stem cells.
    Lin X; Li JJ; Qian WJ; Zhang QJ; Wang ZF; Lu YQ; Dong EL; He J; Wang N; Ma LX; Chen WJ
    Oncotarget; 2017 Jun; 8(26):42030-42042. PubMed ID: 28159932
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of cerebrospinal fluid biomarkers in pediatric patients with spinal muscular atrophy.
    Kobayashi Y; Ishikawa N; Tateishi Y; Izumo H; Eto S; Eguchi Y; Okada S
    Brain Dev; 2023 Jan; 45(1):2-7. PubMed ID: 36210235
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nusinersen ameliorates motor function and prevents motoneuron Cajal body disassembly and abnormal poly(A) RNA distribution in a SMA mouse model.
    Berciano MT; Puente-Bedia A; Medina-Samamé A; Rodríguez-Rey JC; Calderó J; Lafarga M; Tapia O
    Sci Rep; 2020 Jul; 10(1):10738. PubMed ID: 32612161
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The light at the end of the tunnel gets vivid for spinal muscular atrophy: An Editorial Highlight for "Cerebrospinal fluid proteomic profiling in nusinersen-treated patients with spinal muscular atrophy" on page 650.
    Dutta D; Chandra G; Mohanakumar KP
    J Neurochem; 2020 Jun; 153(5):545-548. PubMed ID: 32128827
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cerebrospinal fluid proteomic profiling in nusinersen-treated patients with spinal muscular atrophy.
    Kessler T; Latzer P; Schmid D; Warnken U; Saffari A; Ziegler A; Kollmer J; Möhlenbruch M; Ulfert C; Herweh C; Wildemann B; Wick W; Weiler M
    J Neurochem; 2020 Jun; 153(5):650-661. PubMed ID: 31903607
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.